Bristol-Myers Squibb Company
NYSE-BMY
Company Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Name
Bristol-Myers Squibb Company
CEO
Dr. Christopher S. Boerner Ph.D.
Website
www.bms.com
Sector
Pharmaceuticals
Year Founded
1887
Profile
Market Cap
$100.34B
EV
$147.38B
Shares Out
2,027.4M
Revenue
$46.51B
Employees
34,100
Margins
Gross
76.18%
EBITDA
40.96%
Operating
19.42%
Pre-Tax
-13.8%
Net
-14.06%
FCF
27.83%
Returns (5Yr Avg)
ROA
2.3%
ROTA
-26.16%
ROE
6.59%
ROCE
10.92%
ROIC
9.63%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$53.34
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$6,653M
Net Debt
$46.99B
Debt/Equity
3.16
EBIT/Interest
5.82
Growth (CAGR)
Rev 3Yr
1.57%
Rev 5Yr
14.28%
Rev 10Yr
11.12%
Dil EPS 3Yr
12.45%
Dil EPS 5Yr
-3.25%
Dil EPS 10Yr
7.18%
Rev Fwd 2Yr
1.68%
EBITDA Fwd 2Yr
1%
EPS Fwd 2Yr
-3.55%
EPS LT Growth Est
-5.32%
Dividends
Yield
—
Payout
-73.68%
DPS
$2.37
DPS Growth 3Yr
7.27%
DPS Growth 5Yr
7.77%
DPS Growth 10Yr
5.18%
DPS Growth Fwd 2Yr
4.25%